Boehringer Ingelheim, Eli Lilly present data from studies of diabetes drugs
RIDGEFIELD, Conn., and INDIANAPOLIS — Boehringer Ingelheim and Eli Lilly will present data from their diabetes portfolio at the 47th Annual Meeting of the European Association for the Study of Diabetes in Lisbon, Portugal.
The drug makers will make seven presentations, including study results evaluating linagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, as well as empagliflozin (BI-10773), an investigational sodium-dependent glucose co-transporter-2 (SGLT-2) inhibitor. Additionally, a long-term study evaluating the efficacy and safety of linagliptin in patients with Type 2 diabetes was selected by EASD as an oral presentation.
Linagliptin in the 5-mg strength was approved in May by the Food and Drug Administration under the trade name Tradjenta.
Swiffer boosts products with HD Clean technology
CINCINNATI — Swiffer has updated its products with high-definition technology to offer a deeper clean.
“Swiffer is going beyond traditional methods to deliver a clean so extraordinary that the definition of clean as we know it has been elevated to the idea of ‘high definition,’” P&G’s home care external relations manager Jeff Pierce said. “Consumers will be pleasantly surprised when they use our products and discover the new level of shine and clarity we’re providing.”
Swiffer dry cloths, Swiffer dusters and Swiffer WetJet solution with HD Clean technology currently are available at mass merchandise, drug and grocery retailers nationwide.
Eddie Li to join Novo Nordisk as VP regulatory affairs
PRINCETON, N.J. — Novo Nordisk has appointed a new VP regulatory affairs.
Effective Sept. 12, Eddie Li will lead the drug maker’s U.S. regulatory team and maintain relationships with individuals and agencies outside of Novo Nordisk that play a role in the Food and Drug Administration’s review and approval process, the company said.
Li will report to Anne Philips, corporate VP clinical development, medical and regulatory affairs for North America.